Market research
SENS.LSE Sensyne Health plc
LSE GBP Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 583K
- P/E ratio
- Not available
- Analyst target
- 349
- Dividend yield
- 0.0%
- Beta
- 1.2
Profile
Instrument facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Health Information Services
- ISIN
- GB00BYV3J755
- Market cap
- 583K
- P/E ratio
- Not available
- Analyst target
- 349
- Dividend yield
- 0.0%
- Beta
- 1.2
About
About Sensyne Health plc
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for Covid-19 self-monitoring; DBm-Health, a patient to clinician system that allows health care professionals manage patients with diabetes; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include MagnifEye that allows reading and analysis of diagnostic tests; SEND, an evidence-based digital charting system for vital-signs observations; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; Support-HF, a prescribed digital therapeutic for monitoring heart failure at home; Sense, a clinical AI algorithm engine; SYNE-COV, a COVID-19 patient outcome algorithm; and SYNE-OPS, a real-time operational patient management algorithm. Sensyne Health has strategic research alliance with Bayer and Roche; collaboration agreement with Alexion to study the prevalence and outcomes of patients in certain disease areas; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; research agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma; strategic research agreement with Milton Keynes University Hospital, Somerset, Hampshire, Royal Wolverhampton, and Royal Devon and Exeter NHS Trusts. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
Research context
Sensyne Health plc appears in PyInvesting’s London Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Health Information Services
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SENS.LSE discussion.
5 years, 6 months ago
Sensyne Health plc is currently in a long term downtrend where the price is trading 2.5% below its 200 day moving average.
From a valuation standpoint, the stock is 87.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 56.4.
Sensyne Health plc's total revenue sank by 0.0% to $196K since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 58.5% to $-6M since the same quarter in the previous year.
Based on the above factors, Sensyne Health plc gets an overall score of 1/5.